LILRB1 A Novel Diagnostic B-Cell Marker to Distinguish Neoplastic B Lymphoblasts From Hematogones

被引：4

作者：

Tutusaus, Silvia Saumell ^{[1
,3
]}

Pirruccello, Elaina ^{[1
]}

Fuda, Franklin ^{[1
]}

Churchill, Hywyn ^{[1
]}

Chen, Dong ^{[1
]}

Zhang, Cheng Cheng ^{[2
]}

Chen, Weina ^{[1
]}

机构：

[1] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA

[2] Univ Texas Southwestern Med Ctr Dallas, Dept Physiol, Dallas, TX USA

[3] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Hematol, Expt Hematol, Barcelona, Spain

来源：

AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2021年 / 156卷 / 06期

关键词：

LILRB1; B-lymphoblastic leukemia; Minimal residual disease; Anti-CD19; Anti-CD22; Flow cytometry; MINIMAL RESIDUAL DISEASE; FLOW-CYTOMETRY; RECEPTOR; ANTIGEN; LEUKEMIA;

D O I：

10.1093/ajcp/aqab057

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Objectives: New B-cell markers are needed for monitoring B lymphoblastic leukemia ( B-ALL) in the era of immunotherapies directed against CD19 and CD22. The expression of leukocyte immunoglobulinlike receptor subfamily B member 1 (LILRB1) on hematogones in bone marrow (BM) and neoplastic B lymphoblasts has not yet been systematically investigated. Methods: We assessed LILRB1 expression pattern on B cells in 19 control BMs and 22 B-ALL cases by flow cytometry. Results: In all cases, mature B cells and hematogones exhibited a consistent pattern of LILRB1 expression with variable intensity over different stages of maturation, including a characteristic V-shaped pattern on hematogones. While neoplastic B lymphoblasts in all cases expressed LILRB1, the pattern of expression was distinctly abnormal relative to hematogones (loss of the dynamic pattern in all cases and abnormal expression levels in 83% of cases). Conclusions: LILRB1 is a novel diagnostic B-cell marker to aid in distinguishing neoplastic B lymphoblasts from hematogones.

引用

页码：941 / 949

页数：9

共 16 条

[1] Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily [J].

Banham, AH ;

Colonna, M ;

Cella, M ;

Micklem, KJ ;

Pulford, K ;

Willis, AC ;

Mason, DY .

JOURNAL OF LEUKOCYTE BIOLOGY, 1999, 65 (06) :841-845

[2] Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232 [J].

Borowitz, Michael J. ;

Wood, Brent L. ;

Devidas, Meenakshi ;

Loh, Mignon L. ;

Raetz, Elizabeth A. ;

Salzer, Wanda L. ;

Nachman, James B. ;

Carroll, Andrew J. ;

Heerema, Nyla A. ;

Gastier-Foster, Julie M. ;

Willman, Cheryl L. ;

Dai, Yunfeng ;

Winick, Naomi J. ;

Hunger, Stephen P. ;

Carroll, William L. ;

Larsen, Eric .

BLOOD, 2015, 126 (08) :964-971

[3] Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma - A single institution experience [J].

Chen, Weina ;

Karandikar, Nitin J. ;

McKenna, Robert W. ;

Kroft, Steven H. .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2007, 127 (01) :39-46

[4]

Cherian Sindhu, 2018, Curr Protoc Cytom, V86, pe44, DOI 10.1002/cpcy.44

[5] Immunoreceptor tyrosine-based inhibition motifs:: a quest in the past and future [J].

Daeron, Marc ;

Jaeger, Sebastien ;

Du Pasquier, Louis ;

Vivier, Eric .

IMMUNOLOGICAL REVIEWS, 2008, 224 :11-43

[6] Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry [J].

Fuda, Franklin ;

Chen, Weina .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2018, 13 (06) :455-466

[7] Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors [J].

Kang, Xunlei ;

Kim, Jaehyup ;

Deng, Mi ;

John, Samuel ;

Chen, Heyu ;

Wu, Guojin ;

Phan, Hiep ;

Zhang, Cheng Cheng .

CELL CYCLE, 2016, 15 (01) :25-40

[8] Promoter choice and translational repression determine cell type-specific cell surface density of the inhibitory receptor CD85j expressed on different hematopoietic lineages [J].

Lamar, David L. ;

Weyand, Cornelia M. ;

Goronzy, Joerg J. .

BLOOD, 2010, 115 (16) :3278-3286

[9] CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia [J].

Maude, Shannon L. ;

Teachey, David T. ;

Porter, David L. ;

Grupp, Stephan A. .

BLOOD, 2015, 125 (26) :4017-4023

[10] Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry [J].

McKenna, RW ;

Washington, LT ;

Aquino, DB ;

Picker, LJ ;

Kroft, SH .

BLOOD, 2001, 98 (08) :2498-2507

← 1 2 →